Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 4Phase 1/2 2

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 3Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Stomach Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Colorectal Neoplasms 5Neoplasm Metastasis 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Melanoma 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Biliary Tract Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Solid Tumors 1Solid Tumor 1Sarcoma, Alveolar Soft Part 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Digestive System Neoplasms 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Ramucirumab × Clear all
NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Elevation Oncology

Phase 1 Terminated
88 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

NCT03013218 2025-08-01

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

ALX Oncology Inc.

Phase 1 Completed
174 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

NCT02564198 2021-08-17

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Eli Lilly and Company

Phase 1 Completed
29 enrolled 12 charts
CNS

Neoplasms, Recurrence, Central Nervous System Neoplasms

NCT01285037 2018-02-20

A Study of LY2801653 in Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
190 enrolled
Tumor-Agnostic

Neoplasms

NCT00786383 2013-08-19

Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy

Eli Lilly and Company

Phase 1 Completed
25 enrolled
Tumor-Agnostic

Neoplasms

NCT00793975 2013-08-19

Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy

Eli Lilly and Company

Phase 1 Completed
37 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡